Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- PMID: 31723001
- PMCID: PMC7553241
- DOI: 10.1158/0008-5472.CAN-19-1840
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
Abstract
Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 3' region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+ prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. SIGNIFICANCE: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.
©2019 American Association for Cancer Research.
Conflict of interest statement
Financial support and conflict of interest statements are included at the end of the manuscript.
Figures


Comment in
-
Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.J Urol. 2020 Sep;204(3):619-620. doi: 10.1097/JU.0000000000001176.01. Epub 2020 Jun 26. J Urol. 2020. PMID: 32586171 No abstract available.
References
-
- Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918–21 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA176785/CA/NCI NIH HHS/United States
- C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
- P50 CA116201/CA/NCI NIH HHS/United States
- P50 CA105641/CA/NCI NIH HHS/United States
- R01 CA149429/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
- U10 CA180822/CA/NCI NIH HHS/United States
- U10 CA180868/CA/NCI NIH HHS/United States
- R03 CA130065/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- P20 CA233255/CA/NCI NIH HHS/United States
- R01 CA142996/CA/NCI NIH HHS/United States
- P50 CA125183/CA/NCI NIH HHS/United States
- UM1 CA164920/CA/NCI NIH HHS/United States
- P30 CA168524/CA/NCI NIH HHS/United States
- U01 CA161032/CA/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- 20861/CRUK_/Cancer Research UK/United Kingdom
- U10 CA027469/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U01 CA116167/CA/NCI NIH HHS/United States
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 CA214545/CA/NCI NIH HHS/United States
- C5047/A8385FCCC/CRUK_/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- R01 CA116167/CA/NCI NIH HHS/United States
- C12292/A20861/CRUK_/Cancer Research UK/United Kingdom
- U10 CA037517/CA/NCI NIH HHS/United States
- P20 GM130423/GM/NIGMS NIH HHS/United States
- R25 CA112486/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- T32 CA009001/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- C8197/A16565/CRUK_/Cancer Research UK/United Kingdom
- 10118/CRUK_/Cancer Research UK/United Kingdom
- R01 CA192393/CA/NCI NIH HHS/United States
- 23382/CRUK_/Cancer Research UK/United Kingdom
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous